Telomere length as a predictor of therapy response and survival in patients diagnosed with ovarian carcinoma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Shorter telomere length (TL) in blood predicts chemotherapy response in ovarian cancer (OvC). Tumor TL also correlates with overall survival, offering valuable prognostic insights for OvC patients.
Area Of Science
- Oncology
- Genetics
- Molecular Biology
Background
- Impaired telomere length (TL) maintenance is implicated in epithelial ovarian cancer (OvC) development.
- TL in blood or tumor tissue is being explored as a biomarker for anti-OvC therapy response and disease progression.
- Accurate chemotherapy response prediction is crucial for effective OvC treatment.
Purpose Of The Study
- To investigate the role of TL in peripheral blood leukocytes (PBL) and tumor tissues as a predictor of chemotherapy response and overall survival (OS) in OvC patients.
- To analyze the methylation status and gene expression of the shelterin complex and hTERT in relation to therapy response.
- To identify potential molecular pathways associated with differential treatment outcomes.
Main Methods
- Monochrome multiplex quantitative PCR (qPCR) was used to measure TL in PBL and tumor tissues from 209 OvC patients.
- High-Throughput DNA methylation profiling and RNA sequencing (RNA-Seq) were employed to assess methylation status and gene expression of key genes (shelterin complex, hTERT) in tumor tissues.
- Statistical analyses were performed to correlate TL, gene expression, and methylation with clinical outcomes, including chemotherapy response and OS.
Main Results
- Patients sensitive to chemotherapy exhibited shorter TL in PBL compared to treatment-resistant patients (P=0.037).
- Transcriptomic analysis revealed alterations in the peroxisome proliferator-activated receptor (PPAR) signaling pathway in patients with different therapy responses (q=0.001).
- Shorter tumor TL was associated with better overall survival (OS) (P=0.006), and TPP1 gene expression positively correlated with tumor TL (P=0.026).
Conclusions
- Telomere length (TL) measured in peripheral blood leukocytes (PBL) can serve as a predictive marker for platinum-based chemotherapy response in ovarian cancer (OvC) patients.
- Telomere length (TL) determined in tumor tissue provides valuable prognostic information regarding overall survival (OS) in OvC.
- Alterations in the PPAR signaling pathway and TPP1 gene expression may be linked to treatment response and survival outcomes in OvC.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...